Simplify Health Care ETF Highlights Humana Amid Broader Market Options

Investors looking at the healthcare sector currently have distinct paths to consider, ranging from targeted pharmaceutical indexes to actively managed funds that support philanthropic causes. The Simplify Health Care ETF offers an active approach to medical innovation, featuring a portfolio of 58 holdings with a strong emphasis on medical technology and biotechnology.

The fund allocates approximately 91 percent of its portfolio to healthcare, alongside small tilts toward the consumer cyclical and industrial sectors. Among its largest positions, Humana represents 8.04 percent, followed by Arcutis Biotherapeutics at 7.18 percent and Johnson and Johnson at 7.16 percent. Launched in 2021, the fund features a unique structure by pledging its net management profits to breast cancer research.

In comparison, the State Street SPDR S&P Pharmaceuticals ETF provides a lower-cost, passive index exposure specifically focused on the pharmaceutical and life sciences sub-sector. Maintaining 62 holdings entirely within the healthcare sector, its largest positions include Xeris Biopharma Holdings at 2.68 percent, Pacira Biosciences at 2.60 percent, and Veradermics at 2.37 percent.

When comparing costs and performance metrics, the Simplify fund carries a 0.51 percent expense ratio, which is higher than the 0.35 percent fee associated with the State Street fund. However, the Simplify fund provides a higher distribution yield, offering a yield gap of 0.34 percentage points based on recent trailing figures.

These varied investment vehicles highlight the different strategies available within the medical sector, allowing market participants to choose between broad, actively managed innovation or targeted, index-based pharmaceutical exposure. As market conditions evolve, both funds continue to offer distinct ways to navigate healthcare equities.